Although revenues are expected to grow in subsequent quarters in fiscal 2014, revenue slipped for radiation oncology firm Accuray in its first quarter.
For the period (end-September 30), Accuray had revenues of $76.6 million, down 7% from the $82.7 million reported in the same quarter of 2013. The company had a net loss of $15.5 million, compared with a net loss of $24.1 million a year ago.
Among encouraging signs, Accuray pointed to gross orders of $63.4 million received in the quarter, up 17% from the first fiscal quarter of 2013.
